The majority of premature deaths related to tobacco cigarettes (TCs) are attributable to cardiovascular disease, so it is fitting and timely to review the overall cardiovascular impact of electronic cigarettes (ECs), which have recently exploded onto the tobacco product market. Longitudinal studies of EC users are necessary, but not yet available, to answer the question whether cardiovascular disease is lower in chronic EC users compared to TC smokers, so we must rely on biomarker studies. Several biomarkers that portend increased cardiovascular risk, including markers of increased sympathetic nerve activity, oxidative stress and inflammation, vascular dysfunction, and thrombosis, have been reported to be abnormal after EC use, although often not to the degree found in TC smokers. We conclude that if all FDA-certified strategies for TC smoking cessation have been tried without success, then ECs may be a reasonable strategy for TC smoking cessation, but the message to non-TC smokers must be clear and unwavering: non TC-smokers should not use ECs -they are not harmless.
Electronic cigarettes (ECs) have exploded onto the tobacco product market, accounting for 3.6 billion dollars in sales in the United States in 2018. An estimated 10.8 million (4.5%) adults and 3.05 million (20.8%) high school students in the United States are current EC users, a prevalence that has been described as by the FDA as "an epidemic"(1, 2). ECs have incited impassioned and dramatically divergent reactions among the public and health care communities. On the one hand, ECs have been embraced as a potential lifesaving replacement for lethal tobacco cigarettes (TCs), which kill half of the people who use them. On the other hand, ECs have been vilified as a stealth means, promoted by Big Tobacco, of addicting the next generation to nicotine just when the endgame to TC smoking was in sight.
The majority of premature deaths related to TCs are attributable to cardiovascular disease, so it is fitting and timely to review the overall cardiovascular impact of EC use, and to do this encompassing both perspectives. Afterall, the impact of ECs on cardiovascular risk may be vastly different in the middle-aged breadwinner addicted to TCs who is unable to quit, compared to the young, never-smoking high school student, who "Juuls" in the high school bathroom and sometimes, daringly, even in the classroom.
TC smoking is the most prevalent, preventable risk factor for cardiovascular disease in the United States, thus the impact of any strategy to decrease TC use is likely to have a favorable impact on cardiovascular mortality. Using sophisticated statistical modeling techniques to develop 3 "pessimistic and optimistic e-cigarette substitution scenarios," in which the estimates of the relative cardiovascular risk of ECs compared to TCs is varied, Levy et al. (3) estimated that replacement of TCs by ECs in the United States could yield 1.6 to 6.6 million fewer premature deaths over 10 years (3) . In Great Britain, since the introduction of ECs, the number of TC quit attempts, and importantly, successful TC quit attempts, has significantly increased (4).
Should physicians recommend electronic cigarettes to their patients as an effective smoking cessation strategy?
Until recently, only a few small randomized controlled trials (RCTs), using first generation ECs (less effective nicotine delivery devices compared to 2 nd and 3 rd generation devices), tested the effectiveness of ECs in smoking cessation. In the one available RCT in TC smokers trying to quit, 657 adult TC smokers were randomly assigned to 3 different groups: 1) nicotine (16 mg) EC, 2) placebo EC (no nicotine) and 3) nicotine (21 mg) patch. During the trial, ECs were well tolerated. At six months, verified abstinence rates in the EC groups, with and without nicotine, were similar to those achieved with the nicotine patch (range 4.1 to 7.3%, verified abstinence). In another RCT of ECs as a cessation device, 300 TC smokers not intending to quit were randomized to: 1) 12 weeks of 7.2 mg nicotine ECs, 2) 6 weeks of 7.2 mg nicotine ECs followed by 6 weeks of 5.4 mg nicotine ECs, and 3) 12 weeks of no-nicotine ECs. After 1-year follow-up the investigators reported that ECs were well-tolerated, overall TC quitting was 8.7%, and daily TC consumption 4 was decreased, without significant differences among the groups. Rahman et al. (5) performed a meta-analysis of 7,551 TC smokers using ECs for smoking cessation in 6 studies, including these 2 RCT, 2 cross-sectional studies, and 2 prospective cohort studies. Although the meta-analysis was limited by the heterogeneity of the studies, the authors concluded that ECs with nicotine were more effective than no-nicotine ECs in achieving TC quitting, and that there was insufficient data to compare ECs to certified, U.S. Food and Drug Administration (FDA)-approved cessation strategies.
Only recently have data become available consistent with the superiority of ECs with nicotine over certified nicotine replacement therapies(NRTs), each accompanied by behavioral support, for TC smoking cessation. In this multicenter, pragmatic randomized trial in which almost 900 TC smokers were enrolled, ECs were almost twice as effect as NRTs (18.0% vs 9.9%) in achieving smoking abstinence at one year, confirmed by exhaled carbon monoxide testing (6) . Importantly, however, 80% of those successfully quitting TC smoking were still using ECs at 1 year, whereas only 4% in the NRT group were still using nicotine replacement products.
In summary, emerging evidence supports the concept that ECs are effective TC cessation devices, and that they are superior to certified NRTSs.
However, since the majority of those studied continue to use ECs long-term, the health consequences of long-term EC use is of critical importance, yet remains unknown. Even a 10% misclassification of these TC smokers as EC users would invalidate the conclusions of in this study (13) . Table) Numerous studies are consistent with a hyperadrenergic state in EC users (14, 15) . Heart rate and blood pressure significantly increase following acute EC use (14, 16) . The increases are small, however, and their clinical significance is uncertain. Heart rate variability (HRV) is another measure of sympathetic activation and autonomic balance; persistently increased sympathetic nerve activity as measured by HRV is associated with increased cardiovascular mortality (17) (18) (19) (20) (21, 22) . Abnormal HRV consistent with sympathetic predominance is associated with increased cardiovascular risk in TC smokers (16, 23) . We studied a small group of otherwise healthy, chronic EC users compared to age-matched non-smoking controls, to determine if cardiac sympathetic nerve activity was similarly increased in chronic EC users. We found that HRV was abnormal in chronic EC users, consistent with increased sympathetic nerve activity ( Figure 3 ) (15). The abnormal pattern of HRV was the same pattern that has been associated with increased cardiovascular risk in patients with and without known cardiac disease (17) (18) (19) (20) (21) (22) . In a follow-up study, we compared the effects of nicotine vs the non-nicotine constituents present in EC emissions, and determined that nicotine, not non-nicotine constituents acutely increased sympathetic activated as measured by HRV parameters (14) .
Although exocytotic norepinephrine release from peripheral postganglionic sympathetic nerve endings is an important mechanism underlying the sympathomimetic effects of nicotine (24), it is unlikely the whole explanation for the hyperadrenergic state in EC users. In our study of chronic EC users in whom sympathetic predominance was present, all EC users had 9 abstained from EC use on the day of the study, confirmed by non-detectable plasma nicotine levels drawn simultaneously with the HRV recordings (15) .
This finding of a sustained hyperadrenergic effect, even in the absence of acute nicotine use, mandates that we consider pleomorphic, not just pharmacological effects, of inhaled nicotine.
Nicotinic receptors are present throughout the autonomic nervous system, including the amygdala, a brain area that integrates responses to emotion and stress (25) (26) (27) . Although studies have not been done in chronic EC users, in chronic TC smokers, dysregulation of the amygdala has been reported (26-28). Amygdalar dysregulation impacts control the sympathetic nervous system, and importantly, amygdalar hyperactivity, as detected by Table) Tobacco cigarette smoke contains abundant reactive oxygen species (ROS) that overwhelm natural defense systems; oxidative stress is likely a major mechanism by which TC smoking causes atherosclerosis (30) .
Oxidative stress interferes with nitric oxide generation and bioavailability, increases oxidative modification of LDL particles and therefore their atherosclerotic potential, and induces inflammatory gene activation and amplification (30 following TC smoking. Unfortunately, it is not possible to know if the EC and TC exposures were comparable (1 TC vs 9 puffs of an unspecified EC), since changes in plasma nicotine levels were not measured.
We compared susceptibility to oxidative stress in chronic EC users and non-smoker controls using the biomarker LDL-oxidizability, and found that susceptibility to oxidative stress was significantly greater in chronic EC users In clinical studies of atherosclerosis using 18 F-FDG-PET/CT, increased metabolic activity in hematopoietic tissues, including the bone marrow and spleen, was correlated with vascular inflammation, and has even been shown to confer increased cardiovascular risk (35) (36) (37) . Importantly, we used 18 F-FDG-PET/CT to measure inflammation in hematopoietic and vascular tissues in otherwise healthy chronic EC users, TC smokers, and non-smokers (38). 13 We found that Table) Endothelial dysfunction, as estimated by impaired brachial artery flowmediated dilatation (FMD), is an independent risk factor for cardiovascular disease. FMD has been found to be impaired in chronic TC smokers, and even non-smokers exposed to secondhand smoke (39, 40) . Only one study has measured the effect of EC use on FMD, and this was an acute exposure study in non-smokers and TC smokers. These vascular studies in chronic EC users are sorely needed.
Do electronic cigarettes promote platelet aggregation? (Figure 2,

Table)
Pathological thrombus formation within the coronary artery triggers myocardial ischemia and infarction. Increased platelet activation predisposes to thrombus formation, and anti-platelet therapy with aspirin plays a key role in reducing recurrent myocardial ischemia and infarction. TC smoking increases platelet aggregation, and this increased platelet aggregation is likely a major mechanism by which current TC smoking leads to adverse cardiovascular events (30) (Figure 2 ). To date, only one in vivo study comparing the effects of acute TC smoking and EC use on platelet activation in humans has been published. Nocella et al. (47) found that both acute TC smoking and EC use increased platelet aggregation to a similar degree in 16 chronic TC smokers, but TCs compared with ECs had greater adverse effects on platelets in non-smokers. Since epinephrine induces platelet aggregation, and epinephrine is acutely released by nicotine, perhaps it is not surprising that nicotine ECs increase platelet aggregation in humans. Whether the nonnicotine EC constituents also increase platelet activation is unknown and unstudied. rare that these studies actually report biomarkers in chronic EC users (15, 38) . Most of these studies (33, 34, 44, 46, 47) 
